ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Jul 28, 2015
Best Ideas Newsletter Holding Teva Surges!
Have you been paying attention to the best ideas?
Jul 23, 2015
Guide to Second Quarter Earnings; Big Pharma Experiencing Earnings Momentum
Abbott, Bristol-Myers, Celgene, Eli Lilly, Novartis, Roche, Valeant…
Jul 7, 2015
Teva Pharmaceuticals Committed to Acquiring Mylan
Best Ideas Newsletter portfolio holding Teva Pharmaceuticals is committed to creating a generics industry giant. The deal has great potential, but the companies aren’t seeing eye-to-eye.
Apr 21, 2015
Things for Your Radar Tuesday
What we’re hearing and what we think.
Apr 9, 2015
Mylan’s Deal for Perrigo Boosts Teva
We continue to like the generics business. Teva Pharma leaps to $65+ per share!!!
Feb 5, 2015
Some Wiggle Room, Please
Lots of earnings reports out. Let’s go around the horn.
Jan 5, 2015
4 Opportunistic Stocks To Consider Buying in 2015
The Valuentum Buying Index has registered a high rating in the past on these four investment ideas. 2015 may mark strong gains for these gems.
Dec 1, 2014
Nov 3, 2014
How About Teva Pharmaceuticals?
Teva Pharma has been one of the best performers thus far in 2014, and we trust many of you have profited.
Oct 13, 2014
Performance of the Valuentum Buying Index
Two separate studies have reinforced the efficacy of the Valuentum Buying Index, both as a portfolio optimization tool and as an idea generator. Let's get the thoughts of Valuentum's Brian Nelson on the studies.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.